$353.9 B

JNJ Mkt cap, 03-Aug-2018
Johnson & Johnson Net income (Q2, 2019)8.3 B
Johnson & Johnson Cash, 01-Jul-201817.6 B
Johnson & Johnson EV365.7 B

Johnson & Johnson Revenue

Johnson & Johnson revenue was $71.89 b in FY, 2017 which is a 2.6% year over year increase from the previous period.

Embed Graph

Johnson & Johnson Revenue Breakdown

Embed Graph

Johnson & Johnson revenue breakdown by business segment: 18.5% from Consumer, 46.5% from Pharmaceutical and 34.9% from Medical Devices

Johnson & Johnson Income Statement

Annual

USDFY, 2013FY, 2014FY, 2016FY, 2017

Revenue

71.3 b74.3 b70.1 b71.9 b

Revenue growth, %

4%(6%)3%

Cost of goods sold

22.3 b22.7 b21.5 b21.7 b

Gross profit

49 b51.6 b48.5 b50.2 b

Gross profit Margin, %

69%69%69%70%

Sales and marketing expense

21.8 b22 b21.2 b19.9 b

R&D expense

8.2 b8.5 b9 b9.1 b

Operating expense total

30 b30.4 b30.2 b29 b

Depreciation and amortization

4.1 b3.9 b3.7 b3.8 b

EBIT

16.4 b21.6 b19.2 b16.5 b

EBIT margin, %

23%29%27%23%

Interest expense

580 m533 m552 m726 m

Interest income

74 m67 m128 m368 m

Pre tax profit

15.5 b20.6 b19.2 b19.8 b

Income tax expense

1.6 b4.2 b3.8 b3.3 b

Net Income

13.8 b16.3 b15.4 b16.5 b

Johnson & Johnson Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2016FY, 2017

Cash

20.9 b14.5 b13.7 b19 b

Accounts Receivable

11.7 b11 b10.7 b11.7 b

Prepaid Expenses

4 b3.5 b3 b3.3 b

Inventories

7.9 b8.2 b8.1 b8.1 b

Current Assets

56.4 b59.3 b60.2 b65 b

PP&E

16.7 b16.1 b15.9 b15.9 b

Goodwill

22.8 b21.8 b21.6 b22.8 b

Total Assets

132.7 b131.1 b133.4 b141.2 b

Accounts Payable

6.3 b7.6 b6.7 b6.9 b

Short-term debt

4.9 b3.6 b7 b4.7 b

Current Liabilities

25.7 b25.1 b27.7 b26.3 b

Long-term debt

13.3 b15.1 b12.9 b22.4 b

Total Debt

18.2 b18.8 b19.9 b27.1 b

Total Liabilities

58.6 b61.4 b62.3 b70.8 b

Common Stock

3.1 b3.1 b3.1 b3.1 b

Retained Earnings

89.5 b97.2 b103.9 b110.6 b

Total Equity

74.1 b69.8 b71.2 b70.4 b

Debt to Equity Ratio

0.2 x0.3 x0.3 x0.4 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.2 x

Financial Leverage

1.8 x1.9 x1.9 x2 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

12 b10.6 b13.6 b13.9 b18.6 b18.2 b20.9 b12.6 b15.7 b14.6 b17.6 b

Accounts Receivable

11.5 b12 b11.4 b11.4 b12.1 b11.8 b12.3 b13.3 b13.2 b

Prepaid Expenses

3.7 b3.1 b3 b3.3 b3.1 b2.6 b2.8 b3 b2.9 b

Inventories

8.1 b8.3 b8.2 b8.2 b8.5 b8.5 b8.9 b9.7 b9.5 b9 b8.8 b

Current Assets

58.2 b61 b63.5 b62.7 b66.3 b63.3 b63.3 b38.8 b41.8 b42.8 b45.4 b

PP&E

15.4 b15.6 b15.6 b16 b16 b16.1 b16.2 b16.5 b40.9 b17 b16.6 b

Goodwill

21.3 b21.5 b21.3 b21.8 b22.1 b23.2 b24.8 b31.2 b31.3 b31.1 b30.3 b

Total Assets

129 b132 b133 b136 b140 b140 b145 b153 b155.7 b156.6 b155.4 b

Accounts Payable

6.7 b6.1 b5.9 b6 b6.1 b6 b6.1 b6.1 b6.4 b6.4 b6.5 b

Short-term debt

4 b5.2 b5.7 b3.1 b1.7 b3.4 b5.4 b7.2 b8.5 b

Current Liabilities

23.8 b24.5 b25.3 b22.1 b21.5 b23.2 b25.1 b28.9 b31.8 b27.1 b27.5 b

Long-term debt

14.9 b14.1 b14.1 b20.2 b24.5 b23.5 b27 b27.4 b26.7 b29.8 b29.4 b

Total Debt

19 b19.3 b19.8 b23.3 b26.2 b27 b32.4 b34.6 b35.2 b29.8 b29.4 b

Total Liabilities

60.7 b60.9 b61.7 b63.6 b67.3 b67.6 b74.6 b80.9 b81.7 b93.4 b92.5 b

Common Stock

3.1 b3.1 b3.1 b3.1 b3.1 b3.1 b3.1 b3.1 b3.1 b

Retained Earnings

98.7 b101 b103 b105 b107 b109 b112 b113 b114.8 b104.3 b106.1 b

Total Equity

67.9 b71.1 b71.6 b72.6 b72.5 b72.8 b70.3 b71.9 b74 b63.3 b62.9 b

Debt to Equity Ratio

0.3 x0.3 x0.3 x0.3 x0.4 x0.4 x0.5 x0.5 x0.5 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

1.9 x1.9 x1.9 x1.9 x1.9 x1.9 x2.1 x2.1 x2.1 x2.5 x2.5 x

Johnson & Johnson Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

13.8 b16.3 b15.4 b16.5 b

Depreciation and Amortization

4.1 b3.9 b3.7 b3.8 b

Accounts Receivable

(632 m)(247 m)(433 m)(1.1 b)

Inventories

(622 m)(1.1 b)(449 m)(249 m)

Accounts Payable

1.8 b955 m(3 m)656 m

Cash From Operating Activities

17.4 b18.5 b19.3 b18.8 b

Purchases of PP&E

(3.6 b)(3.7 b)(3.5 b)(3.2 b)

Cash From Investing Activities

(5.1 b)(12.3 b)(7.7 b)(4.8 b)

Short-term Borrowings

(1.4 b)(1.3 b)(1 b)(2 b)

Long-term Borrowings

(1.6 b)(1.8 b)(68 m)(2.2 b)

Cash From Financing Activities

(6.1 b)(12.3 b)(10.8 b)(8.6 b)

Net Change in Cash

6 b(6.4 b)(791 m)5.2 b

Interest Paid

596 m603 m515 m730 m

Income Taxes Paid

3.2 b3.5 b2.9 b2.8 b

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

4.3 b8.8 b12.2 b4.3 b8.5 b12.7 b4.4 b8.2 b12 b4.4 b8.3 b

Depreciation and Amortization

895 m1.8 b2.7 b891 m1.8 b2.7 b912 m2.1 b3.8 b

Accounts Receivable

(765 m)(1.2 b)(910 m)(389 m)(1.1 b)(736 m)(96 m)(476 m)(300 m)(479 m)(989 m)

Inventories

(276 m)(537 m)(719 m)(190 m)(443 m)(408 m)(368 m)(421 m)(193 m)(322 m)(491 m)

Accounts Payable

(2.5 b)(2.2 b)1.6 b(2.3 b)(1 b)(1.2 b)(2 b)(1.2 b)339 m

Cash From Operating Activities

2.9 b8.1 b14.2 b1.8 b6.8 b12.1 b2.9 b8.7 b15 b3.6 b9.7 b

Purchases of PP&E

(543 m)(1.3 b)(2.1 b)(639 m)(1.4 b)(2.1 b)(560 m)(1.2 b)(2 b)(658 m)(1.5 b)

Cash From Investing Activities

(1.8 b)(5.3 b)(6.3 b)(1.5 b)(215 m)(2.6 b)(936 m)(13.2 b)(14.4 b)(925 m)(1.1 b)

Short-term Borrowings

(193 m)(345 m)(930 m)(4.2 b)(4.7 b)(3.9 b)(195 m)(180 m)(936 m)

Long-term Borrowings

(16 m)(21 m)(27 m)(14 m)(936 m)(953 m)(2 m)(15 m)(1 b)

Cash From Financing Activities

(3.2 b)(5.7 b)(7.6 b)(178 m)(1.6 b)(5.1 b)(150 m)(2.1 b)(4.1 b)(6 b)(8.6 b)

Net Change in Cash

(2.5 b)(3.9 b)(884 m)129 m4.9 b4.5 b1.9 b(6.4 b)(3.3 b)

Johnson & Johnson Ratios

USDY, 2018

EV/CFO

37.8 x

Financial Leverage

2.5 x
Report incorrect company information

Johnson & Johnson Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Manufacturing Facilities

134 121 119 125

Facilities

265 250 230 260

Countries

60 60 60 60

Discovery Projects

100 150

Drugs Approved by FDA

2
Report incorrect company information